Alto Neuroscience’s (ANRO) Buy Rating Reiterated at HC Wainwright

Alto Neuroscience (NYSE:ANRO)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $50.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 128.10% from the company’s current price.

ANRO has been the subject of a number of other research reports. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a research report on Monday, March 16th. Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. BTIG Research boosted their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Wedbush decreased their target price on shares of Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, Robert W. Baird raised their target price on shares of Alto Neuroscience from $22.00 to $41.00 and gave the stock an “outperform” rating in a report on Wednesday, March 18th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.57.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO traded down $1.49 during trading hours on Thursday, reaching $21.92. 395,172 shares of the stock were exchanged, compared to its average volume of 251,039. The firm has a market capitalization of $700.26 million, a price-to-earnings ratio of -10.06 and a beta of 2.52. The stock’s fifty day simple moving average is $19.09 and its 200 day simple moving average is $14.63. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $25.17.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. Sell-side analysts predict that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Investors Weigh In On Alto Neuroscience

A number of large investors have recently modified their holdings of the business. Torren Management LLC bought a new position in shares of Alto Neuroscience in the 4th quarter valued at $62,000. Balyasny Asset Management L.P. bought a new stake in shares of Alto Neuroscience during the 4th quarter worth $198,000. OMERS ADMINISTRATION Corp acquired a new stake in Alto Neuroscience in the fourth quarter valued at about $221,000. Vanguard Personalized Indexing Management LLC boosted its stake in Alto Neuroscience by 13.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after buying an additional 2,055 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new position in Alto Neuroscience in the fourth quarter valued at about $304,000.

Key Stories Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating and set a $30.00 price target (about 40% upside from current levels), providing some buy-side support amid the trial news. Chardan reaffirmed buy
• Positive Sentiment: JonesTrading cut its price target from $49 to $44 but kept a “buy” rating, leaving a large implied upside that may attract value-seeking investors if confidence in the broader pipeline holds. JonesTrading lowers PT but stays buy
• Neutral Sentiment: Company announces a strategic pivot: Alto is shifting focus to ALTO-207 after the ALTO-101 topline readout — this indicates pipeline prioritization but brings execution and timeline uncertainty. Alto shifts focus to ALTO-207
• Negative Sentiment: Alto reported that ALTO-101 did not reach statistical significance on the trial’s primary endpoint — the core reason for the stock sell-off and heightened short-term risk to valuation. Topline data announcement
• Negative Sentiment: Market coverage highlights the trial miss and accompanying stock decline, reinforcing negative sentiment among investors and media. Investing.com coverage
• Negative Sentiment: Additional reporting on the failed schizophrenia study amplifies investor concern about ALTO-101 and near-term commercial prospects. MSN article
• Negative Sentiment: Wedbush trimmed its price target to $21.00 and moved to “neutral,” signaling diminished near-term upside and adding downward pressure from the sell-side. Wedbush lowers PT to neutral

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.